4
Changes in Ownership
IONIS PHARMACEUTICALS INC Filed Acc 0000874015-23-000235
EVP, Chief Development Officer sold 10,612 shares at an average $49.50 ($525,324)
- EVP, Chief Development Officer acquired 10,612 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Geary Richard S · EVP, Chief Development Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-12-20 | Exercise or conversion : show line 1 in the form 10b5-1 | +6,500 | $47.34 | $307,710 | 79,461 | D |
| 2023-12-20 | Sale : show line 2 in the form 10b5-1 | −6,500 | $49.64 | $322,643 | 72,961 | D |
| 2023-12-21 | Exercise or conversion : show line 3 in the form 10b5-1 | +4,112 | $47.34 | $194,662 | 77,073 | D |
| 2023-12-21 | Sale : show line 4 in the form 10b5-1 | −4,112 | $49.29 | $202,681 | 72,961 | D |
| Open-market sales · 10,612 sh · avg $49.50 · $525,324 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2023-12-20 | Exercise or conversion : show line 5 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −6,500 | $47.34 | 2024-01-02 | 6,500 | 4,112 | D |
| 2023-12-21 | Exercise or conversion : show line 6 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −4,112 | $47.34 | 2024-01-02 | 4,112 | 0 | D |
Loading xslF345X05/edgardoc.xml…